Latest News
News
FDA committee recommends approval of tofacitinib for PsA
The FDA Arthritis Advisory Committee voted 10-1 in favor of approval of tofacitinib for psoriatic arthritis.
Latest News
First interchangeability study for an adalimumab biosimilar has begun
The trial recently enrolled its first patient.
Conference Coverage
Unresolved fatigue lingers for most PsA patients
MADRID – Three factors appear most responsible for the majority of reported patient fatigue.
Conference Coverage
Children with psoriasis face multitude of comorbidities
CHICAGO – Obesity ranks as the most well-understood comorbidity of psoriasis in children. Furthermore, many obese children with psoriasis may also...
Conference Coverage
Ixekizumab helps PsA patients who failed a TNFi
MADRID – Ixekizumab appears to be a good second-line choice for TNFi-unresponsive patients.
News
First IL-23 blocker, guselkumab, earns FDA approval for psoriasis
The approved indication is for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Conference Coverage
Comorbidities in psoriatic arthritis flag worse prognosis
MADRID - Focus on comorbidities to improve treatment.
News
FDA approves abatacept for adults with psoriatic arthritis
The approval expands the approved indications of abatacept to three autoimmune diseases.
Conference Coverage
Early phase III data positive for adalimumab biosimilar, for both psoriasis and PsA
Response curves were nearly identical for adalimumab and the biosimilar
Conference Coverage
Ustekinumab trumps TNF-blockade for enthesitis in patients with psoriatic arthritis
After 6 months, 71% of those taking ustekinumab showed total enthesitis clearance.